NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, Forecast & News

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) issued its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. The biotechnology company earned $20.86 million during the quarter, compared to analyst estimates of $16.27 million. Rigel Pharmaceuticals had a negative net margin of 56.84% and a negative return on equity of 52.74%. During the same quarter last year, the business posted ($0.14) EPS. View Rigel Pharmaceuticals' Earnings History.

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Rigel Pharmaceuticals.

Rigel Pharmaceuticals issued an update on its fourth quarter 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15.4-15.4 million, compared to the consensus revenue estimate of $15.14 million.

4 equities research analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 175.7% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.

News stories about RIGL stock have trended very negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Rigel Pharmaceuticals.

Rigel Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 11,070,000 shares, a decline of 6.5% from the December 15th total of 11,840,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is presently 7.7 days. Approximately 6.8% of the company's shares are short sold. View Rigel Pharmaceuticals' Current Options Chain.

Some companies that are related to Rigel Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Geron (GERN), Terra Tech (TRTC), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Fate Therapeutics (FATE), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Rigel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.13%), DNB Asset Management AS (0.09%) and Assenagon Asset Management S.A. (0.08%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Dean L Schorno, Eldon C Mayer III, Nelson Cabatuan and Raul R Rodriguez. View Institutional Ownership Trends for Rigel Pharmaceuticals.

RIGL stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Rigel Pharmaceuticals.

RIGL stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Dean L Schorno, Eldon C Mayer III and Raul R Rodriguez. View Insider Buying and Selling for Rigel Pharmaceuticals.

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RIGL stock can currently be purchased for approximately $2.72.

Rigel Pharmaceuticals has a market capitalization of $455.90 million and generates $44.51 million in revenue each year. The biotechnology company earns $-70,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.View Additional Information About Rigel Pharmaceuticals.

The official website for Rigel Pharmaceuticals is http://www.rigel.com/.

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]